https://en.bioecon.ru/capabilities/celltherapy/Recent content in Celltherapy on BioeconHugoen-USTue, 18 Aug 2026 22:19:08 +0700https://en.bioecon.ru/technology/car-t-cell-therapy/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/car-t-cell-therapy/A patient’s own T cells are collected, engineered with a chimeric antigen receptor (CAR) using a lentiviral vector, expanded and re-infused to kill cancer — an approved one-time living-drug class spanning CD19 lymphoma/leukemia and BCMA multiple myeloma, now advancing toward off-the-shelf allogeneic products.https://en.bioecon.ru/technology/stem-cell-therapy-autoimmune/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/stem-cell-therapy-autoimmune/Living mesenchymal stromal cells (MSC) or regulatory T cells (Treg) are infused to re-tolerise the immune system in autoimmune and inflammatory disease — an approved-asset class led by Mesoblast’s Ryoncil for steroid-refractory GVHD and TiGenix’s Alofisel for Crohn’s fistula, with a deeper engineered-Treg pipeline for lupus, arthritis and aplastic anemia.https://en.bioecon.ru/technology/tcr-therapy/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/tcr-therapy/Patient T cells are engineered with a high-affinity T-cell receptor (TCR) that recognises a peptide-MHC complex inside a solid-tumour cell — an approved one-time therapy reaching tumour targets CAR-T cannot, led by Adaptimmune’s Tecelra and Immunocore’s Kimmtrak, with a deeper pipeline advancing MAGE-A4, NY-ESO-1, gp100 and PRAME targets.https://en.bioecon.ru/technology/nk-cell-car-nk-therapy/Fri, 19 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/nk-cell-car-nk-therapy/CAR-NK and NK-cell therapy — allogeneic, off-the-shelf effector cells with low toxicity (minimal CRS, no GVHD) against solid and haematological cancers; iPSC-NK is the scalable platform.https://en.bioecon.ru/technology/til-therapy/Fri, 19 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/til-therapy/TIL therapy — autologous tumor-infiltrating T-cells with polyclonal specificity; the first approved drug Lifileucel (Amtagvi, Iovance, FDA 2024) is a breakthrough in metastatic melanoma.